Toremifene: An evaluation of its safety profile

Breast

Volumn 15, Issue 2, 2006, Pages 142-157

  Harvey, Harold A ^a   Kimura, Morihiko ^b   Hajba, Alajos ^c  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b Gunma Cancer Center   (Japan)

^c ORION CORPORATION   (Finland)

Author keywords

Antiestrogens; Endometrial safety; Hepatotoxicity; Oculotoxicity; Toremifene; Vascular complications

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL; ESTRADIOL DERIVATIVE; ESTROGEN; LETROZOLE; ORAL CONTRACEPTIVE AGENT; OSPEMIFENE; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE;

ALOPECIA; ATHEROSCLEROSIS; BONE DENSITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER RISK; CATARACT; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COLORECTAL CANCER; DEEP VEIN THROMBOSIS; DIGESTIVE SYSTEM CANCER; DISEASE EXACERBATION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SUBSTITUTION; ENDOMETRIUM CANCER; ESTROGEN THERAPY; EYE TOXICITY; FOLLOW UP; FRACTURE; GENOTOXICITY; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; HYPOCHOLESTEROLEMIA; LIVER CANCER; LIVER CIRRHOSIS; LIVER TOXICITY; LUNG EMBOLISM; META ANALYSIS; MULTIMODALITY CANCER THERAPY; NONALCOHOLIC FATTY LIVER; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; PARTIAL MASTECTOMY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; SECOND CANCER; SKIN TOXICITY; STOMACH CANCER; SYSTEMATIC REVIEW; TRANSIENT ISCHEMIC ATTACK; UTERUS DISEASE; VENOUS THROMBOEMBOLISM; BREAST TUMOR; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CHEMICALLY INDUCED DISORDER; ENDOMETRIUM TUMOR; FEMALE; NEOPLASM; PATHOLOGY;

BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CLINICAL TRIALS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TOREMIFENE;

EID: 33746310357     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2005.09.007     Document Type: Review

References (154)

1. Hayes D., Van Zyl J., Hacking A., Goedhals L., Bezwoda W., Mailliard J., et al. Randomised comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 13 (1995) 2556-2566
2. Gershanovich M., Garin A., Baltina D., Kurvet A., Kangas L., Ellmén J., and Eastern European Study Group. A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Breast Cancer Res Treat 45 (1997) 251-262
3. Pyrhönen S., Valavaara R., Modig H., Pawlicki M., Pienkowski T., Gundersen S., et al. Comparison of toremifene and tamoxifen in postmenopausal patients with advanced breast cancer: a randomised double-blind, the "Nordic" phase III study. Br J Cancer 76 (1997) 270-277
4. Pyrhönen S., Ellmén Vuorinen J., Gershanovich M., Tominaga T., Kaufmann M., et al. Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer. Breast Cancer Res Treat 56 (1999) 133-143
5. Holli K., Valavaara R., Blanco G., Kataja V., Hietanen P., Flander M., et al. Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group. J Clin Oncol 18 (2000) 3487-3494
6. International Breast Cancer Study Group. Toremifene and tamoxifen are equally effective for early stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93. Ann Oncol 15 (2004) 1749-1759
7. Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90 (1998) 1371-1388
8. Cuzick J., Forbes J., Edwards R., Baum M., Cawthorn S., Coates A., et al., IBIS investigators. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 360 (2002) 817-824
9. Milla-Santos A., Milla- L., Rallo L., and Solano V. Phase III trial of toremifene vs tamoxifen in hormonodependent breast cancer. Breast Cancer Res Treat 65 (2001) 119-124
10. Williams G.M., and Jeffrey A.M. Safety assessment of tamoxifen and toremifene. Oncology (Williston Park) 11 (1997) 41-47
11. Kuramochi H. Conformational studies and electronic structures of tamoxifen and toremifene and their allylic carbocations proposed as reactive intermediates leading to DNA adduct formation. J Med Chem 39 (1996) 2877-2886
12. Cummings F.J. Evolving uses of hormonal agents for breast cancer. Clin Ther 24 suppl. C (2002) C3-C25
13. Cummings S.R., Eckert S., Krueger K.A., Grady D., Powles T.J., Cauley J.A., et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281 (1999) 2189-2197
14. The ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62
15. Fornander T., Rutqvist L.E., Cedermark B., Glas U., Mattsson A., Silfversward C., et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1 8630 (1989) 117-120
16. Fornander T., Hellstrom A.C., and Moberger B. Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J Natl Cancer Inst 85 (1993) 1850-1855
17. Rutqvist L.E., Johansson H., Signomklao T., Johansson U., Fornander T., and Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J Natl Cancer Inst 87 (1995) 645-651
18. Fisher B., Costantino J.P., Redmond C.K., Fisher E.R., Wickerham D.L., and Cronin W.M. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86 (1994) 527-537
19. Mignotte H., Lasset C., Bonadona V., Lesur A., Luporsi E., Rodier J.F., et al. Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study. Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC). Int J Cancer 76 (1998) 325-330
20. Bernstein L., Deapen D., Cerhan J.R., Schwartz S.M., Liff J., McGann-Maloney E., et al. Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 91 (1999) 1654-1662
21. Bergman L., Beelen M.L., Gallee M.P., Hollema H., Benraadt J., and van Leeuwen F.E. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of liver and endometrial cancer risk following tamoxifen. Lancet 356 (2000) 881-887
22. Pukkala E., Kyyronen P., Sankila R., and Holli K. Tamoxifen and toremifene treatment of breast cancer and risk of subsequent endometrial cancer: a population-based case-control study. Int J Cancer 100 (2002) 337-341
23. Braithwaite R.S., Chlebowski R.T., Lau J., George S., Hess R., and Col N.F. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 18 (2003) 937-947
24. Gail M., Costantino J., Bryant J., Croyle R., Freedman L., Helzlsouer K., et al. Weighing the risk and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 91 (1999) 1829-1846
25. Riggs L., and Hartmann L. Selective estrogen-receptor modulators-mechanism of action and application in clinical practice. N Engl J Med 348 (2003) 618-629
26. Dignam J.J., and Fisher B. Occurrence of stroke with tamoxifen in NSABP B-24. Lancet 355 (2000) 848-849
27. Harvey H., and Hajba A. Stroke incidence with toremifene is lower than with tamoxifen in breast cancer patients. Proc ASCO 22 (2003) 741 (Abstract 2981)
28. McDonald C.C., Alexander F.E., Whyte B.W., Forrest A.P., Stewart H.J., and The Scottish Cancer Trials Breast Group. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. BMJ 311 (1995) 977-980
29. Reis S.E., Costantino J.P., Wickerham D.L., Tan-Chiu E., Wang J., and Kavanah M. Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators. J Natl Cancer Inst 93 (2001) 16-21
30. Law C.H., and Tandan V.R. The association between tamoxifen and the development of hepatocellular carcinoma: case report and literature review. Can J Surg 42 (1999) 211-214
31. Taniya T., Noguchi M., Tajiri K., Nakano Y., Kitabayashi K., Miyazaki I., et al. A case report of hyperlipemia with giant fatty liver during adjuvant endocrine therapy by tamoxifen. Gan No Rinsho 33 (1987) 300-304
32. Chishima T, Suda T. Effect of change in toremifene administration on hypertriglyceridemia induced by tamoxifen administration in postoperative breast cancer patients. First congress of the world society for breast health, 23-26 September 2001, Istanbul, Turkey, 2001, Abstract.
33. Pinto H.C., Baptista A., Camilo M.E., de Costa E.B., Valente A., and de Moura M.C. Tamoxifen-associated steatohepatitis-report of three cases. J Hepatol 23 (1995) 95-97
34. Pratt D.S., Knox T.A., and Erban J. Tamoxifen-induced steatohepatitis. Ann Intern Med 123 (1995) 236
35. Van Hoof M., Rahier J., and Horsmans Y. Tamoxifen-induced steatohepatitis. Ann Intern Med 124 (1996) 855-856
36. Oien K.A., Moffat D., Curry G.W., Dickson J., Habeshaw T., Mills P.R., et al. Cirrhosis with steatohepatitis after adjuvant tamoxifen. Lancet 353 (1996) 36-37
37. Cai Q., Bensen M., Greene R., and Kirchner J. Tamoxifen-induced transient multifocal hepatic fatty infiltration. Am J Gastroenterol 95 (2000) 277-279
38. Dray X., Tainturier M.H., De La Lande P., Marty O., and Mallet L. Cirrhosis with non alcoholic steatohepatitis: role of tamoxifen. Gastroenterol Clin Biol 24 (2000) 1122-1123
39. Lasso De La Vega M.C., Zapater P., Such J., Sola-Vera J., Paya A., Horga J.F., et al. Toxic hepatitis associated with tamoxifen use. A case report and literature review. Gastroenterol Hepatol 25 (2002) 247-250
40. Kanda T., Yokosuka O., Chiba T., Kojima H., Fukai K., Imazeki F., et al. A case of steatohepatitis associated with tamoxifen. Nippon Shokakibyo Gakkai Zassh 99 (2002) 1119-1121
41. Saibara T., Onishi S., Ogawa Y., Yoshida S., and Enzan H. Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis. Lancet 353 (1999) 1802
42. Newcomb P.A., Solomon C., and White E. Tamoxifen and risk of large bowel cancer in women with breast cancer. Breast Cancer Res Treat 53 (1999) 271-277
43. Cook L.S., Weiss N.S., Pharris-Ciurej N., Schwartz S.M., and White E. Colorectal cancer following tamoxifen therapy for breast cancer (United States). Cancer Causes Control 12 (2001) 405-410
44. Grodstein F., Newcomb P.A., and Stampfer M.J. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 106 (1999) 574-582
45. Al-Azzawi F., and Wahab M. Estrogen and colon cancer: current issues. Climacteric 5 (2002) 3-14
46. Ding X., and Kaminsky L.S. Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol 43 (2002) 149-173
47. Kaiser-Kupfer M.I., and Lippman M.E. Tamoxifen retinopathy. Cancer Treat Rep 62 (1978) 315-320
48. Kaiser-Kupfer M.I., Kupfer C., and Rodrigues M.M. Tamoxifen retinopathy. A clinicopathologic report. Ophthalmology 88 (1981) 89-93
49. McKeown C.A., Swartz M., Blom J., and Maggiano J.M. Tamoxifen retinopathy. Br J Ophthalmol 65 (1981) 177-179
50. Vinding T., and Nielsen N.V. Retinopathy caused by treatment with tamoxifen in low dosage. Acta Ophthalmol (Copenh) 61 (1983) 45-50
51. Griffiths M.F. Tamoxifen retinopathy at low dosage. Am J Ophthalmol 104 (1987) 185-186
52. Gerner E.W. Ocular toxicity of tamoxifen. Ann Ophthalmol 21 (1989) 420-423
53. Costa R.H., Dhooge M.R., Van Wing F., and De Rouck A.F. Tamoxifen retinopathy. A case report. Bull Soc Belge Ophtalmol 238 (1990) 161-168
54. Chern S., and Danis R.P. Retinopathy associated with low-dose tamoxifen. Am J Ophthalmol 116 (1993) 372-373
55. Nayfield S., and Gorin M.B. Tamoxifen-associated eye disease: a review. J Clin Oncol 14 (1996) 1018-1026
56. Lee A.G. Tamoxifen retinopathy. J Neuroophthalmol 18 (1998) 276
57. Sommer S., Badet J.C., Zaoui M., Naoun-Hubert I., and Rozot P. Birdshot chorioretinopathy associated with tamoxifen retinal toxicity. J Fr Ophtalmol 23 (2000) 494-497
58. Alwitry A., and Gardner I. Tamoxifen maculopathy. Arch Ophthalmol 120 (2002) 1402
59. Yanyali A.C., Freund K.B., Sorenson J.A., Slakter J.S., and Wheatley H.M. Tamoxifen retinopathy in a male patient. Am J Ophthalmol 131 (2001) 386-387
60. Pavlidis N.A., Petris C., Briassoulis E., Klouvas G., Psilas C., Rempapis J., et al. Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients. Cancer 69 (1992) 2961-2964
61. Noureddin B.N., Seoud M., Bashshur Z., Salem Z., Shamseddin A., and Khalil A. Ocular toxicity in low-dose tamoxifen: a prospective study. Eye 13 (1999) 729-733
62. Tang R., Shields J., Schiffman J., Li H., Locher D., Hampton J., et al. Retinal changes associated with tamoxifen treatment for breast cancer. Eye 11 (1997) 295-297
63. Lazzaroni F., Scorolli L., Pizzoleo C.F., Savini G., De Nigris A., Giosa F., et al. Tamoxifen retinopathy: does it really exist?. Graefes Arch Clin Exp Ophthalmol 236 (1998) 669-673
64. Barrett-Connor E., Grady D., Sashegyi A., Anderson P.W., Cox D.A., Hoszowski K., et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 287 (2002) 847-857
65. Harper-Wynne C, Ross G, Sacks N, Dowsett M. A pilot prevention study of the aromatase inhibitor letrozole: effect on breast cell proliferation and bone/lipid indices in healthy postmenopausal women. Breast cancer research treatment special issue: 24th annual San Antonio breast cancer symposium, 2001;69:225, Abstract 136.
66. Weed D.L. Methodologic guidelines for review papers. J Natl Cancer Inst 89 (1997) 6-7
67. Oxman A.D. Checklists for review articles. BMJ 304 (1994) 648-651
68. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351 (1998) 1451-1467
69. Matsuyama Y., Tominaga T., Nomura Y., Koyama H., Kimura M., Sano M., et al. Second cancers after adjuvant tamoxifen therapy for breast cancer in Japan. Ann Oncol 11 (2000) 1537-1543
70. Erkkola R., Nevala P., and Mäntylä E. Toremifene and breast cancer therapy: incidence of secondary endometrial cancers. Breast Cancer Res Treat 76 suppl. 1 (2002) 156 (Abstract 636)
71. Mäenpää J., Ellmen J., Pasanen T., and Kaukonen M. Re: effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth. J Natl Cancer Inst 91 (1999) 972-973
72. Mäenpää J., Holli K., and Pasanen T. Toremifene. Where do we stand?. Eur J Cancer 36 suppl. 4 (2000) S61-S62
73. Bertelli G., Queirolo P., Vecchio S., Angiolini C., Bergaglio M., Del Mastro l., et al. Toremifene as a substitute for adjuvant tamoxifen in breast cancer patients. Anticancer Res 20 (2000) 3659-3662
74. Kim S.Y., Suzuki N., Laxmi Y.R.S., Rieger R., and Shibutani S. Alpha hydroxylation of tamoxifen and toremifene by human and rat cytochrome P450 3A subfamily enzymes. Chem Res Toxicol 16 (2003) 1138-1144
75. Phillips D.H. Understanding the genotoxicity of tamoxifen?. Carcinogenesis 22 (2001) 839-849
76. Hard G.C., Iatropoulos M.J., Jordan K., Radi L., Kaltenberg O.P., Imondi A.R., et al. Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. Cancer Res 53 (1993) 4534-4541
77. Davies R., Oreffo V.I., Martin E.A., Festing M.F., White I.N., Smith L.L., et al. Tamoxifen causes gene mutations in the livers of lambda/lacI transgenic rats. Cancer Res 57 (1997) 1288-1293
78. Rajaniemi H., Mantyla E., and Hemminki K. DNA adduct formation by tamoxifen and structurally related compounds in rat liver. Chem Biol Interact 113 (1998) 145-159
79. Rajaniemi H., Koskinen M., Mantyla E., and Hemminki K. DNA binding of tamoxifen and its analogues: identification of the tamoxifen-DNA adducts in rat liver. Toxicol Lett 102-103 (1998) 453-457
80. 14C]radiolabelled tamoxifen or toremifene to rat DNA using accelerator mass spectrometry. Chem Biol Interact 106 (1997) 149-160
81. Williams G.M., Iatropoulos M.J., Djordjevic M.V., and Kaltenberg O.P. The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis 14 (1993) 315-317
82. Montandon F., and Williams G.M. Comparison of DNA reactivity of the polyphenylethylene hormonal agents diethylstilbestrol, tamoxifen and toremifene in rat and hamster liver. Arch Toxicol 68 (1994) 272-275
83. Carthew P., Martin E.A., White I.N., De Matteis F., Edwards R.E., Dorman B.M., et al. Tamoxifen induces short-term cumulative DNA damage and liver tumors in rats: promotion by phenobarbital. Cancer Res 55 (1995) 544-547
84. Williams G.M., Iatropoulos M.J., and Karlsson S. Initiating activity of the anti-estrogen tamoxifen, but not toremifene in rat liver. Carcinogenesis 18 (1997) 2247-2253
85. Carthew P., Lee P.N., Edwards R.E., Heydon R.T., Nolan B.M., and Martin E.A. Cumulative exposure to tamoxifen: DNA adducts and liver cancer in the rat. Arch Toxicol 75 (2001) 375-380
86. Dragan Y.P., Fahey S., Nuwaysir E., Sattler C., Babcock K., Vaughan J., et al. The effect of tamoxifen and two of its non-isomerizable fixed-ring analogs on multistage rat hepatocarcinogenesis. Carcinogenesis 17 (1996) 585-594
87. Ahotupa M., Hirsimaki P., Parssinen R., and Mantyla E. Alterations of drug metabolizing and antioxidant enzyme activities during tamoxifen-induced hepatocarcinogenesis in the rat. Carcinogenesis 15 (1994) 863-868
88. Karlsson S., Hirsimaki Y., Mantyla E., Nieminen L., Kangas L., Hirsimaki P., et al. A two-year dietary carcinogenicity study of the antiestrogen toremifene in Sprague-Dawley rats. Drug Chem Toxicol 19 (1996) 245-266
89. Williams G.M., Ross P.M., Jeffrey A.M., and Karlsson S. Genotoxicity studies with the antiestrogen toremifene. Drug Chem Toxicol 21 (1998) 449-476
90. Martin E.A., Rich K.J., White I.N., Woods K.L., Powles T.J., and Smith L.L. 32P-postlabelled DNA adducts in liver obtained from women treated with tamoxifen. Carcinogenesis 16 (1995) 1651-1654
91. Hu F.B., and Grodstein F. Postmenopausal hormone therapy and the risk of cardiovascular disease: the epidemiologic evidence. Am J Cardiol 90 1A (2002) 26F-29F
92. Pines A., Bornstein N.M., and Shapira I. Menopause and ischaemic stroke: basic, clinical and epidemiological considerations. The role of hormone replacement. Hum Reprod Update 8 (2002) 161-168
93. Wise P.M., Dubal D.B., Wilson M.E., Rau S.W., and Bottner M. Minireview: neuroprotective effects of estrogen-new insights into mechanisms of action. Endocrinology 142 (2001) 969-973
94. Grady D., Wenger N.K., Herrington D., Khan S., Furberg C., Hunninghake D., et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Ann Int Med 132 (2000) 689-696
95. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomised controlled trial. JAMA 288 (2002) 321-333
96. Gillum L.A., Mamidipudi S.K., and Johnston S.C. Ischemic stroke risk with oral contraceptives: a meta-analysis. JAMA 284 (2000) 72-78
97. Kinsinger L.S., Harris R., Woolf S.H., Sox H.C., and Lohr K.N. Chemoprevention of breast cancer: a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med 137 (2002) 59-69
98. Thürlimann B., and The BIG 1-98 Collaborative Group. Letrozole versus tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor positive breast cancer. BIG 1-98: a prospective randomized double blind phase III study. Breast 14 suppl. 1 (2005) (Abstract S4)
99. Fisher B., Dignam J., Wolmark N., Wickerham D.L., Fisher E.R., Mamounas E., et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 353 (1999) 1993-2000
100. Gylling H., Pyrhonen S., Mantyla E., Mäenpää H., Kangas L., and Miettinen T.A. Tamoxifen and toremifene lower serum cholesterol by inhibition of delta 8-cholesterol conversion to lathosterol in women with breast cancer. J Clin Oncol 13 (1995) 2900-2905
101. Saarto T., Blomqvist C., Ehnholm C., Taskinen M.R., and Elomaa I. Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. J Clin Oncol 14 (1996) 429-433
102. Joensuu H., Holli K., Oksanen H., and Valavaara R. Serum lipid levels during and after adjuvant toremifene or tamoxifen therapy for breast cancer. Breast Cancer Res Treat 63 (2000) 225-234
103. Kusama M., Kaise H., Nakayama S., Ota D., Misaka T., and Aoki T. Crossover trial for lipid abnormality in postmenopausal breast cancer patients during selective estrogen receptor modulators (SERMs) adminstrations. Breast Cancer Res Treat 88 (2004) 9-16
104. Kataja V., Hietanen P., Joensuu H., Ala-Luhta T., Asola R., Kokko R., et al., for the Finnish Breast Cancer Group (FBCG). The effects of adjuvant anastrozole, exemestane, tamoxifen and toremifene on serum lipids in postmenopausal women with breast cancer-a randomised study. Breast Cancer Res Treat 76 suppl. 1 (2002) S156 (Abstract 634)
105. Miyauchi K., Sano M., Kimura M., Mitsuyama S., Aoyama H., Kusama M., et al. Effect of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer. Proc ASCO 22 (2003) (Abstract 165)
106. Marttunen M.B., Hietanen P., Tiitinen A., Viinikka L., and Ylikorkala O. Antiestrogens reduce plasma levels of endothelin-1 without affecting nitrate levels in breast cancer patients. Gynecol Endocrinol 14 (2000) 55-59
107. Brun L.D., Gagne C., Rousseau C., Moorjani S., and Lupien P.J. Severe lipemia induced by tamoxifen. Cancer 57 (1986) 2123-2126
108. Kozo K., Masaru S., Norio H., Kazushige F., Naruaki M., Kunio T., and Masahiko M. Tamoxifen induced severe hypertriglyceridaemia-report of 3 cases. Gan To Kagaku Ryoho 31 (2004) 1109-1112
109. Bradbury B.D., Lash T.L., Kaye J.A., and Jick S.S. Tamoxifen-treated breast carcinoma patients and the risk of acute myocardial infarction and newly diagnosed angina. Cancer 103 (2005) 1114-1121
110. Hamada N., Ogawa Y., Saibara T., Murata Y., Kariya S., Nishioka A., et al. Toremifene-induced fatty liver and NASH in breast cancer patients with breast-conservation treatment. Int J Oncol 17 (2000) 1119-1123
111. Nishino M., Hayakawa K., Nakamura Y., Morimoto T., and Mukaihara S. Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer: high frequency of involvement and rapid reversal after completion of tamoxifen therapy. Am J Roentgenol 180 (2003) 129-134
112. Maeenpaeae H., Saransaari P., and Taehti H. Kinetics of inhibition of glutamate uptake by antiestrogens. Pharmacol Toxicol 93 (2003) 174-179
113. Riggs B.L., Khosla S., and Melton L.J. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 23 (2002) 279-302
114. Sverrisdottir A., Fornander T., Jacobsson H., von Schoultz E., and Rutqvist L.E. Bone mineral density among premenopausal women with early breast cancer in a randomised trial of adjuvant therapy. J Clin Oncol 22 (2004) 3694-3699
115. Powles T.J., Hickish T., Kanis J.A., and Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14 (1996) 78-84
116. Jordan V.C., Phelps E., and Lindgren J.U. Effects of anti-estrogens on bone in castrated and intact female rats. Breast Cancer Res Treat 10 (1987) 31-35
117. Fornander T., Rutqvist L.E., Sjoberg H.E., Blomqvist L., Mattsson A., and Glas U. Long-term adjuvant tamoxifen in early breast cancer: effect on bone mineral density in postmenopausal women. J Clin Oncol 8 (1990) 1019-1024
118. Tiitinen A., Nikander E., Hietanen P., Metsae-Heikkilae M., and Ylikorkala O. Changes in bone mineral density during and after 3 years' use of tamoxifen or toremifene. Maturitas 48 (2004) 321-327
119. Saarto T., Blomqvist C., Valimaki M., Makela P., Sarna S., and Elomaa I. Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens. Br J Cancer 75 (1997) 602-605
120. Marttunen M.B., Hietanen P., Tiitinen A., and Ylikorkala O. Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. J Clin Endocrinol Metab 83 (1998) 1158-1162
121. Saarto T., Vehmanen L., Elomaa I., Valimaki M., Makela P., and Blomqvist C. The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer. Br J Cancer 20 84 (2001) 1047-1051
122. Marttunen M.B., Hietanen P., Titinen A., Roth H.J., Viinikka L., and Ylikorkala O. Effects of tamoxifen and toremifene on urinary excretion of pyridinoline and deoxypyridinoline and bone density in postmenopausal patients with breast cancer. Calcif Tissue Int 65 (1999) 365-368
123. Scarpellini F., and Sbracia M. A controlled trial between hormone replacement therapy and toremifene in post-menopausal women aged 65 years old or more. Fertil Steril 4 (2000) 188 (Abstract P-298)
124. Sorbera L.A., Castañer J., and Bayés M. Ospemifene. Drugs Future 29 (2004) 38-44
125. Komi J., Heikkinen J., Rutanen M., Halonen K., Lammintausta R., and Ylikorkala O. Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women. Gynecol Endocrinol 18 (2004) 152-158
126. Shah M.G., and Maibach H.I. Estrogen and skin. An overview. Am J Clin Dermatol 2 (2001) 143-150
127. Archer C.B., and Smith N.P. Alopecia neoplastica responsive to tamoxifen. J R Soc Med 83 (1990) 647-648
128. Gateley C.A., and Bundred N.J. Alopecia and breast disease. BMJ 314 (1997) 481
129. Ayoub J.P., Valero V., and Hortobagyi G.N. Tamoxifen-induced female androgenetic alopecia in a patient with breast cancer. Ann Intern Med 126 (1997) 745-746
130. Puglisi F., Aprile G., and Sobrero A. Tamoxifen-induced total alopecia. Ann Intern Med 134 (2001) 1154-1155
131. Bostrom A., Sjolin-Forsberg G., Wilking N., and Bergh J. Radiation recall-another call with tamoxifen. Acta Oncol 38 (1999) 955-959
132. Marttunen M.B., Cacciatore B., Hietanen P., Pyrhonen S., Tiitinen A., Wahlstrom T., et al. Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women. Br J Cancer 84 (2001) 897-902
133. Ismail S.M. Pathology of endometrium treated with tamoxifen. J Clin Pathol 47 (1994) 827-833
134. White I.N. Anti-oestrogenic drugs and endometrial cancers. Toxicol Lett 120 (2001) 21-29
135. Hukkanen J., Mantyla M., Kangas L., Wirta P., Hakkola J., Paakki P., et al. Expression of cytochrome P450 genes encoding enzymes active in the metabolism of tamoxifen in human uterine endometrium. Pharmacol Toxicol 82 (1998) 93-97
136. Hemminki K., Rajaniemi H., Lindahl B., and Moberger B. Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Res 56 (1996) 4374-4377
137. Shibutani S., Suzuki N., Terashima I., Sugarman S.M., Grollman A.P., and Pearl M.L. Tamoxifen-DNA adducts detected in the endometrium of women treated with tamoxifen. Chem Res Toxicol 12 (1999) 646-653
138. Shibutani S., Ravindernath A., Suzuki N., Terashima I., Sugarman S.M., Grollman A.P., et al. Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen. Carcinogenesis 21 (2000) 1461-1467
139. Carmichael P.L., Ugwumadu A.H., Neven P., Hewer A.J., Poon G.K., and Phillips D.H. Lack of genotoxicity of tamoxifen in human endometrium. Cancer Res 56 (1996) 1475-1479
140. Carmichael P.L., Sardar S., Crooks N., Neven P., Van Hoof I., Ugwumadu A., et al. Lack of evidence from HPLC 32P-post-labelling for tamoxifen-DNA adducts in the human endometrium. Carcinogenesis 20 (1999) 339-342
141. Magriples U., Naftolin F., Schwartz P.E., and Carcangiu M.L. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 11 (1993) 485-490
142. Deligdisch L., Kalir T., Cohen C.J., de Latour M., Le Bouedec G., and Penault-Llorca F. Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer. Gynecol Oncol 78 (2000) 181-186
143. Barakat R.R., Wong G., Curtin J.P., Vlamis V., and Hoskins W.J. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol Oncol 55 (1994) 164-168
144. Olson S.H., Finstad C.L., Harlap S., Kurian L., Saigo P.E., and Barakat R.R. A case-case analysis of factors related to overexpression of p53 in endometrial cancer following breast cancer. Cancer Epidemiol Biomarkers Prev 6 (1997) 815-817
145. Ramondetta L.M., Palazzo J.P., Dunton C.J., Kovatich A.J., and Carlson J.A. A comparative analysis of Ki-67, p53, and p21WAF1CIP1 expression in tamoxifen associated endometrial carcinomas. Anticancer Res 18 (1998) 4661-4665
146. Kuwashima Y., Kurosumi M., Kobayashi Y., Tanuma J., Suemasu K., Higashi Y., et al. Random nuclear p53 overexpression pattern in tamoxifen-mediated endometrial carcinoma. Int J Gynecol Pathol 17 (1998) 135-139
147. Shibutani S., Ravindernath A., Terashima I., Suzuki N., Laxmi Y.R., Kanno Y., et al. Mechanism of lower genotoxicity of toremifene compared with tamoxifen. Cancer Res 61 (2001) 3925-3931
148. Hellmann-Blumberg U., Cartner M.G., Wurz G.T., and DeGregorio M.W. Intrinsic reactivity of tamoxifen and toremifene metabolites with DNA. Breast Cancer Res Treat 50 (1998) 135-141
149. Carthew P., Edwards R.E., Nolan B.M., Martin E.A., Heydon R.T., White I.N., et al. Tamoxifen induces endometrial and vaginal cancer in rats in the absence of endometrial hyperplasia. Carcinogenesis 21 (2000) 793-797
150. Newbold R.R., Jefferson W.N., Padilla-Burgos E., and Bullock B.C. Uterine carcinoma in mice treated neonatally with tamoxifen. Carcinogenesis 18 (1997) 2293-2298
151. Mantyla E.T.E., Karlsson S.H., and Nieminen L.S. Induction of endometrial cancer by tamoxifen in the rat. In: Li J.J., Li S.A., Gustafsson J., Nandi S., and Sekely L.I. (Eds). Hormonal carcinogenesis II (1996), Springer, New York 442-445
152. Greaves P., Goonetilleke R., Nunn G., Topham J., and Orton T. Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res 53 (1993) 3919-3924
153. Early Breast Cancer Trialists Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an over view of the randomised trials. Lancet 365 (2005) 1687-1717
154. Dowsett M. Origin and characteristics of adverse events in aromatase inhibition therapy for breast cancer. Semin Oncol 30 suppl. 14 (2003) 58-69